FLT3 and acute myeloid leukemia: Currently, several novel agents acting through distinct molecular targets, identified in the pathophysiology of AML, are being investigated alone or combined with conventional chemotherapy, e.g., FLT3 inhibitors (midostaurin19, gilteritinib20), IDH1/2 inhibitors (ivosidenib21, enasidenib22,23), BCL-2 inhibitor (venetoclax24,25), and cyclin-dependent kinase (CDK) inhibitors (CDKi; alvocidib26–28, fadraciclib29), which cause cell cycle arrest and induce apoptosis.